People with atopic dermatitis, commonly known as eczema, may find that inflammation of the skin is just one of the health conditions theyre living with.
Dermatologists have been aware of an association between eczema and other health concerns. Now, after evaluating data from numerous studies, the American Academy of Dermatology (AAD) has produced an official guideline, which was released at the beginning of the year.
The analysis, published in the Journal of the American Academy of Dermatology in January, found strong evidence tying atopic dermatitis in adults to a number of diseases and conditions, including hay fever, asthma, and food allergies; alopecia (sudden hair loss) and chronic urticaria (hives); osteoporosis; mental health disorders like depression; and skin infections.
When it comes to substance abuse disorder, ADHD (attention deficit hyperactivity disorder), and metabolic syndrome (a group of five conditions that can lead to heart disease, diabetes, stroke, and other health problems), study authors identified some evidence linking these issues to eczema.
The report also suggested a link between atopic dermatitis and various cardiovascular issues, but this association was considered to be small. Evidence supporting a link between eczema and autism spectrum disorders, heart attack, and stroke was inconclusive.
The lead author of the guideline,Dawn Davis, MD,a dermatologist at the Mayo Clinic, calls the AAD guideline groundbreaking because its the first paper of its kind to give a comprehensive review of how eczema may be related to these other physical and mental problems.
We are realizing more and more that inflammatory skin disease such as atopic dermatitis and psoriasis are not only skin conditions, but rather affect the entire person, says Dr. Davis. So we need to practice whole-person care. This guideline is created to empower patients, and to empower the medical community to help patients better address their skin needs.
For decades, dermatologists have recognized a connection between eczema and other atopic and allergic conditions. (The word atopic itself indicates an association with allergies.) MedlinePlus says that up to 60 percent of people with atopic dermatitis develop asthma or hay fever (allergic rhinitis) later in life, and up to 30 percent have food allergies.
Eczema can often signal the beginning of a progression of allergic diseases known as atopic march or allergic march. After people develop eczema, a typical pattern is for them to develop food allergies, followed by hay fever and then asthma.
This new AAD guideline found that about a quarter of adults with eczema had asthma, and they were three times more likely to have this inflammation of the airways than the general population.
The research also spotlighted evidence suggesting that asthma in children ages 7 to 11 was linked to a more persistent type of eczema. Targeted biologic therapies such as dupilumab (Dupixent) demonstrated a potential benefit for both severe atopic dermatitis and asthma.
Dupilumab has been approved for asthma and eczema because both of these diseases kind of work through the same pathway and cause inflammation, says Karan Lal, MD,the committee chair for the Society for Pediatric Dermatology. Its possible if were treating eczema with dupilumab at a very early age, we may prevent [children] from developing clinical signs of asthma.
When it comes to food allergies, researchers estimated that just over 1 in 10 individuals with eczema were likely to have this condition. While the researchers were unclear as to what the implications may be, they pointed out that patients often ask whether food allergies are a trigger for their eczema and whether they should seek out testing for food allergies.
The AAD team observed a consistent link between allergic rhinitis (hay fever) and eczema but little data showing a relationship to allergic conjunctivitis (inflammation of eye tissue) and eosinophilic esophagitis (inflammation of the esophagus).
We always suspected and knew in practice that asthma, food allergies, and other atopic diseases such as allergic rhinoconjunctivitis were more common in patients with eczema, but now we have research data to support those conclusions, says Davis.
Davis stressed that the study confirmed that certain skin diseases are more common in atopic dermatitis patients, such as alopecia areata an autoimmune disease in which the immune system attacks hair follicles, causing sudden hair loss that often results in bald patches on the head and that can affect the hair on other parts of the body as well.
The guideline presented data demonstrating a strong association between eczema and the autoimmune condition chronic urticaria (hives).
Overall, if you have eczema, youre 2.5 times more likely to have an autoimmune condition, according to the new guideline.
An analysis that pooled four studies, including 11,244 adults with eczema and 149,713 people without the condition, found that individuals with eczema faced double the odds of self-reported or clinician-diagnosed depression. In addition, researchers found that eczema patients were more likely to consider suicide, but evidence linking the condition to actual death by suicide was weak.
As to why these patients may be more apt than the general public to have mental health issues, the AAD panel believes that itching, poor sleep, and decreased quality of life overall may play an extensive role.
Although some research made a connection between substance abuse and eczema, evidence was limited about any tie between the skin condition and alcohol use or cigarette smoking.
Davis and her collaborators underscored that ADHD and autism spectrum disorders are better studied in children rather than adults, and these connections will be explored more in depth in an upcoming pediatric guideline.
Atopic disease patients have increased levels of blood proteins connected with cardiovascular risk.
Because systematic inflammation is an established risk factor for cardiovascular disease, its possible that treatments that manage inflammatory skin diseases like eczema could decrease the likelihood of heart problems, according to the guideline.
But in general, the research found only a slight link between eczema and hypertension, peripheral and coronary artery disease, congestive heart failure, and events such as myocardial infarction and cardiovascular death.
The data suggested a small association between eczema and obesity and dyslipidemia (an imbalance of lipids such as cholesterol). Still, pooled facts from eight cross-sectional studies revealed that eczema patients were 36 percent more likely to be obese and 13 percent more likely to have high cholesterol than the general population.
The guideline authors pointed out that atopic dermatitis may actually have an inverse relationship with diabetes, with some research suggesting that individuals have a lower risk of diabetes overall and type 2 diabetes specifically. Based on data analyzed in this paper, however, Davis emphasized that patients with eczema may face a greater likelihood of metabolic syndrome as a whole.
Davis and her team highlighted an investigation demonstrating an increased risk of osteoporosis among those with eczema, and a separate study showed a heightened likelihood of bone fracture. For those with severe atopic dermatitis, the possibility of fracture due to osteoporosis was even greater.
Investigators noted that more research is needed to understand the mechanisms behind this association, but some explanations suggest that chronic systemic inflammation may have a negative effect on bone metabolism, leading to increased bone loss.
The connection between eczema and staphylococcal skin infections is well known. The guideline spotlights a study from the United Kingdom indicating that herpes superinfection is twice as common among those with eczema. Other data suggested cutaneous infections, bacterial skin infections, and eczema herpeticum (a painful, blistering rash caused by the herpes simplex virus) are all more likely to occur among people with eczema.
While Golara Honari, MD, a dermatologist with Stanford Medicine, sees the value in raising awareness about eczemas link to other diseases, she believes patients and doctors need to interpret these correlations with caution.
We need to learn more about these conditions in relation to atopic disease, says Dr. Honari, using cardiovascular disease as an example. There are other common skin diseases for example, psoriasis that have really solid evidence for increased risk of cardiovascular disease, but for atopic dermatitis, that evidence is still not very solid.
Were putting together associations, but we have to be careful, because I don't think these associations necessarily lead to clinical correlations, adds Dr. Lal. Do the results in the guideline mean that for patients that come in, I have to screen all my patients for metabolic syndrome because they have a diagnosis of eczema? It doesn't really work like that.
Overall, Davis and her colleagues view the new guideline as a tool to educate and empower and not induce fear.
When we know certain diseases are interrelated, then we can work on monitoring for those diseases and screening for them, and we can work on lifestyle modification factors that can alter the risk of a disease course, she says.
Visit link:
Eczema Linked to Potential for Other Health Problems - Everyday Health
- Guselkumab Demonstrates Significant Improvement in Psoriasis Symptoms and HRQoL, Reduces Sexual Impairment ... - Dermatology Times - April 18th, 2024 [April 18th, 2024]
- Psoriasis Patients with Arthralgia At Increased Risk of Psoriatic Arthritis Development - MD Magazine - April 18th, 2024 [April 18th, 2024]
- Diagnosing Psoriatic Arthritis for the Dermatologist: Guidance From the Experts - Medscape - April 18th, 2024 [April 18th, 2024]
- Secukinumab 300 mg May Improve PsA or Active Psoriasis More Than 150 mg - MD Magazine - April 18th, 2024 [April 18th, 2024]
- The Impact of Pediatric Plaque Psoriasis on Children and Caregivers - HMP Global Learning Network - April 18th, 2024 [April 18th, 2024]
- Guselkumab Led to Improvements Over Several Psoriatic Arthritis Disease Domains - MD Magazine - April 18th, 2024 [April 18th, 2024]
- Dual Diagnosing and Managing Psoriasis and Psoriatic Arthritis - The Dermatologist - April 18th, 2024 [April 18th, 2024]
- Etanercept Effective for Psoriasis, Rheumatic Disease Among Patients Extending Treatment After 12-Weeks - MD Magazine - February 9th, 2024 [February 9th, 2024]
- High Response Rates in Psoriasis With Oral IL-23 Inhibitor - Medpage Today - February 9th, 2024 [February 9th, 2024]
- Psoriasis and eczema have complex causes and consequences that researchers are seeking to uncover - Medical Xpress - February 9th, 2024 [February 9th, 2024]
- New Hope in Treatment of Plaque Psoriasis: Study Shows Promising Results - Medriva - February 9th, 2024 [February 9th, 2024]
- No Difference in Psoriasis Immune Response Despite Switch Between AVT02, Adalimumab - MD Magazine - February 9th, 2024 [February 9th, 2024]
- Oral IL-23 Receptor Antagonist Peptide Effective in PASI Reduction for Psoriasis - MD Magazine - February 9th, 2024 [February 9th, 2024]
- Breakthrough in Psoriasis Treatment: JNJ-77242113 Shows Promising Results - Medriva - February 9th, 2024 [February 9th, 2024]
- Promising Results from Phase II Trial of Oral Interleukin Inhibitor for Psoriasis Treatment - Medriva - February 9th, 2024 [February 9th, 2024]
- Promising Results from the FRONTIER 1 Trial - An Exploration of JNJ-77242113 in the Treatment of Moderate-to ... - Medriva - February 9th, 2024 [February 9th, 2024]
- Personal Experience with Psoriatic Arthritis and Atopic Dermatitis - Medriva - February 9th, 2024 [February 9th, 2024]
- Rising Cost of Stelara: Impact on Patients and Johnson & Johnson's Market Performance - Medriva - February 9th, 2024 [February 9th, 2024]
- Global Psoriatic Arthritis (PsA) Treatment Market to achieve a remarkable US$ 15.6 Billion by 2028, - PharmiWeb.com - February 9th, 2024 [February 9th, 2024]
- Tremfya potential highlighted by industry analyst GlobalData - The Pharma Letter - May 31st, 2023 [May 31st, 2023]
- Stress Leads to Increased Risk of Depression, Anxiety for Psoriasis ... - MD Magazine - May 31st, 2023 [May 31st, 2023]
- Janssen Announces Positive Results From Guselkumab Psoriatic ... - Dermatology Times - May 31st, 2023 [May 31st, 2023]
- Early Intervention with Secukinumab May Be Effective for Patients ... - MD Magazine - May 31st, 2023 [May 31st, 2023]
- VEGF-A Inhibition Downregulates Blood Vessel Area in Psoriasis - Dermatology Times - May 31st, 2023 [May 31st, 2023]
- Scratching the itch, Lynk Pharmaceuticals trialling ointment for ... - OutSourcing-Pharma.com - May 31st, 2023 [May 31st, 2023]
- Brepocitinib More Efficacious Than Placebo in Long-Term Psoriatic ... - Dermatology Times - May 31st, 2023 [May 31st, 2023]
- For Patients With Birthmarks, Psychosocial Interventions Improved ... - Dermatology Times - May 31st, 2023 [May 31st, 2023]
- Robert Hariri, MD: Natural Killer Cell Therapy Shows Remarkable ... - MD Magazine - May 31st, 2023 [May 31st, 2023]
- Nalbuphine ER Tablets Show Promise as Cough Therapy in ... - MD Magazine - May 31st, 2023 [May 31st, 2023]
- Benefit of Empagliflozin in HFpEF Consistent Regardless of Diuretic ... - MD Magazine - May 31st, 2023 [May 31st, 2023]
- selectION reports results from SAD stage of si-544 Phase Ib trial - Clinical Trials Arena - May 31st, 2023 [May 31st, 2023]
- No Link Observed Between Gastrointestinal Tract Surgery and New ... - MD Magazine - May 30th, 2023 [May 30th, 2023]
- Lynk doses first cohort in Phase Ib trial of psoriasis therapy - Clinical Trials Arena - May 30th, 2023 [May 30th, 2023]
- Metabolic Inflammation Contributes to Depression in Psoriatic Disease - Dermatology Times - May 30th, 2023 [May 30th, 2023]
- Encouraging Diversity and Inclusion for Patients With Psoriatic ... - MD Magazine - May 30th, 2023 [May 30th, 2023]
- The Weekly Roundup: May 22-26 - Dermatology Times - May 30th, 2023 [May 30th, 2023]
- Pediatric Psoriasis Market: A Study of the Industry's Key Applications ... - The Navajo Post - May 30th, 2023 [May 30th, 2023]
- Phototherapy Lamps Market are set to witness a CAGR of 5.8 ... - Digital Journal - May 30th, 2023 [May 30th, 2023]
- Celltrion seeks approval for Stelara biosimilar in EU - The Investor - May 30th, 2023 [May 30th, 2023]
- Peter Marinkovich, MD: FDA Approval of B-VEC Gene Therapy for ... - MD Magazine - May 30th, 2023 [May 30th, 2023]
- Nick Stucky, MD, Phd: Implications for Media Influence on Minoxidil ... - MD Magazine - May 30th, 2023 [May 30th, 2023]
- Tildrakizumab Linked With HRQOL Improvement in Psoriasis in a Real-World Setting - AJMC.com Managed Markets Network - May 18th, 2023 [May 18th, 2023]
- Clinical Utility of Deucravacitinib for the Management of Moderate to ... - Dove Medical Press - May 18th, 2023 [May 18th, 2023]
- Covid-19 and Psoriasis: Is there a link? - Dunya News - May 18th, 2023 [May 18th, 2023]
- Improvement Needed in Study Interventions to Better Skin Self ... - AJMC.com Managed Markets Network - May 18th, 2023 [May 18th, 2023]
- Reviva Pharmaceuticals Announces Intent to File an IND for Brilaroxazine in Psoriasis After Promising Preclinical Data - Marketscreener.com - May 18th, 2023 [May 18th, 2023]
- Adam Friedman, MD: Addressing Disparities in Care for Patients ... - MD Magazine - May 18th, 2023 [May 18th, 2023]
- Early-Infancy Meningitis Infection Linked With Increased Risk of ... - AJMC.com Managed Markets Network - May 18th, 2023 [May 18th, 2023]
- NOVN: Counting Down to PDUFA - Yahoo Finance - May 18th, 2023 [May 18th, 2023]
- Psoriatic Arthritis (PsA) Treatment Market is likely to register CAGR ... - Future Market Insights - May 18th, 2023 [May 18th, 2023]
- New campaign raises awareness of topical steroid withdrawal - Professional Beauty - May 18th, 2023 [May 18th, 2023]
- MoonLake Immunotherapeutics completes patient enrollment and randomization ahead of schedule in a Phase 2 trial of the Nanobody sonelokimab in... - February 2nd, 2023 [February 2nd, 2023]
- EVELO BIOSCIENCES, INC. : Costs Associated with Exit or Disposal Activities, Change in Directors or Principal Officers, Other Events (form 8-K) -... - February 2nd, 2023 [February 2nd, 2023]
- 12 Ways to Treat Psoriasis at Home - Healthline - January 22nd, 2023 [January 22nd, 2023]
- DTC Advertising Of Prescription Drugs In The U.S. Often Promotes Products With Comparatively Low Therapeutic Value - Forbes - January 19th, 2023 [January 19th, 2023]
- Types of Psoriasis: Pictures, Symptoms and Treatments - Healthline - December 18th, 2022 [December 18th, 2022]
- Psoriasis Pathogenesis and Treatment - PMC - PubMed Central (PMC) - November 23rd, 2022 [November 23rd, 2022]
- Drug-Provoked Psoriasis: Is It Drug Induced or Drug Aggravated? - November 23rd, 2022 [November 23rd, 2022]
- Im a Dermatologist and These 7 Things Could Be Making Your Psoriasis Worse - Well+Good - October 19th, 2022 [October 19th, 2022]
- 'Worst time of the year for me to be covered in scabs': Amber Heard's Alleged Ex Cara Delevingne Revealed Her Psoriasis Struggle Made Kate Moss Scream... - October 19th, 2022 [October 19th, 2022]
- Psoriasis: What It Is, Symptoms, Causes, Types & Treatment - October 17th, 2022 [October 17th, 2022]
- What is psoriasis and which foods ease symptoms? - Evening Standard - October 17th, 2022 [October 17th, 2022]
- Chronic inflammatory diseases: what they are - Emergency Live International - October 17th, 2022 [October 17th, 2022]
- How remote care can deliver a step change in treatment for inflammatory skin conditions - PoliticsHome - October 17th, 2022 [October 17th, 2022]
- Probiotics Supplementation may Improve Symptoms of Hyperuricemia and Gout - Rheumatology Network - October 15th, 2022 [October 15th, 2022]
- Psoriasis Pathogenesis and Treatment - PubMed - October 2nd, 2022 [October 2nd, 2022]
- Best and Worst Drinks for Psoriasis - Everyday Health - October 2nd, 2022 [October 2nd, 2022]
- These Are the 10 Most Common Chronic Skin Conditionsand the Most Important Facts to Know About Them - Parade Magazine - October 2nd, 2022 [October 2nd, 2022]
- Survey Addresses Concerns Regarding Reproductive Healthcare Communication in Women with RA, PsA - Rheumatology Network - October 2nd, 2022 [October 2nd, 2022]
- Psoriasis Types, Symptoms & Causes | NIAMS - September 29th, 2022 [September 29th, 2022]
- What Is Psoriasis And Can It Be Treated? - Forbes - September 29th, 2022 [September 29th, 2022]
- Plaque Psoriasis Treated With Tildrakizumab Shown to be Effective in Real-World Settings - MD Magazine - September 29th, 2022 [September 29th, 2022]
- Alumis Announces Initiation of Patient Dosing in Phase 2 Clinical Trial of ESK-001 for the Treatment of Plaque Psoriasis - Business Wire - September 29th, 2022 [September 29th, 2022]
- 15 Items That Will Make Your Life With Psoriatic Arthritis Easier - BlackDoctor.Org - September 29th, 2022 [September 29th, 2022]
- Types of Psoriasis and Their Effects on the Immune System - Cureus - September 27th, 2022 [September 27th, 2022]
- MoonLake Immunotherapeutics to initiate global Phase 2 study of the Nanobody sonelokimab in patients with active psoriatic arthritis - BioSpace - September 27th, 2022 [September 27th, 2022]
- How diversity and inclusion continues to be incorporated in dermatology - PMLiVE - September 27th, 2022 [September 27th, 2022]
- Arcutis Announces Topline Results From ARRECTOR Pivotal Phase 3 Trial Of Roflumilast Foam 0.3% In Scalp A - Benzinga - September 27th, 2022 [September 27th, 2022]
- Psoriasis Treatment Market Size to Hit USD 51.24 Bn by 2030 - GlobeNewswire - August 15th, 2022 [August 15th, 2022]
- Ventyx Sees Initiation Of Mid-Stage Psoriasis Study In Q4 2022 Following Positive Data From Initial-Stage - Benzinga - August 15th, 2022 [August 15th, 2022]